Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Becton Dickinson and Co (BDX) vs Consolidated Edison, Inc. (ED) Price & Performance

Becton Dickinson and CoTrade
Consolidated Edison, Inc.Trade

Price performance (Past 24H)

Key statistics

Becton Dickinson and Co vs Consolidated Edison, Inc. — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Consolidated Edison, Inc. trades at $107.5 (market cap $39.31B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Consolidated Edison, Inc. pays the higher dividend (3.3%). Which is the better fit depends on your goals.

BDXED
Market Cap
$48.93B$39.31B
Sector
HealthUtilities
52-Week High
$185.39$115.46
52-Week Low
$138.62$95.37
Enterprise Value
$65.03B$66.16B
Dividend Yield
2.34%3.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Consolidated Edison, Inc.

Consolidated Edison (ED) trades at $107.98, down 0.89% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The utility reported strong Q2 2026 earnings of $0.83 per share, beating estimates, with revenue growth driven by higher electric and gas rates. Analyst consensus remains cautious with 63% hold ratings and a $103.25 price target below current levels. The company maintains stable dividends and benefits from regulated monopoly positioning in New York.

ED offers defensive utility exposure with predictable cash flows and a 3.2% dividend yield, supported by mid-8% rate base growth and 9.4% allowed ROE through 2029. However, high debt levels ($27.3B total debt), capital-intensive grid upgrades, and regulatory risks present challenges. Current valuation at 17.8x P/E appears fair relative to earnings growth, making it suitable for income-focused investors seeking stability amid market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX

About Consolidated Edison, Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.

Read more on ED